SCAI 2022 Scientific Sessions

1. Abstracts can include a maximum of three image uploads in the following accepted file formats: JPG, JPEG, PNG, and GIF. Abstracts must contain the following four sections, which must not exceed a combined total of 1,900 characters: Background, Methods, Results, and Conclusions. Please also note that each image upload counts as 500 characters.  
2. Abstracts that have been previously published or presented will NOT be eligible for presentation at SCAI. If your abstract is accepted for presentation at another meeting or published prior to SCAI 2022 Scientific Sessions, you must notify SCAI immediately to withdraw your abstract.  
3. Case studies will NOT be accepted or considered for abstract poster presentation at the SCAI 2022 Scientific Sessions. SCAI has a separate call for cases where you should submit your interesting cases and case reports.  
4. Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected.  
5. The SCAI Program Committee endorses the position of the American Association for the Advancement for Science (AAAS) in requiring assurances of the responsible use of animals in research. All submissions for consideration must follow these guidelines.  
6. Abstract submissions must fit into one of the following categories: 
   • Acute Coronary Syndromes and Myocardial Infarction (MI)  
   • Adult Congenital  
   • Angiogenesis, Myogenesis, Cell Therapy, and Gene Therapy  
   • Cardiogenic Shock and Hemodynamic Support  
   • Carotid Interventions  
   • Complex Percutaneous Coronary Intervention (PCI) and Restenosis (Excluding Left Main and Multivessel Intervention)  
   • Imaging: Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), and Noninvasive Imaging  
   • Intervention for Stable Ischemic Heart Disease  
   • Intravascular Imaging (Intravascular Ultrasound [IVUS]/Optical Coherence Topography [OCT]/Near Infrared [NIR]/Other) and Physiology (Fractional Flow Reserve [FFR]/Instantaneous Wave-Free Ratio [iFR]/Index of Microcirculatory Resistance [IMR]/Other)  
   • Left Main and Multivessel Intervention  
   • Miscellaneous  
   • Other Endovascular Interventions (Including Renal Denervation and Abdominal Aortic Aneurysm [AAA])  
   • Pediatric  
   • Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI)  
   • Pharmacotherapy  
   • Pulmonary Embolism  
   • Quality Improvement  
   • Structural Heart Disease (Excluding Valvular Interventions)  
   • Thrombectomy and Vulnerable Plaque  
   • Transcatheter Aortic Valve Replacement (TAVR)  
   • Valvular Interventions (Excluding TAVR)  
   • Vascular Access and Arterial Closure Devices  
   • Venous Disease (Including Deep Vein Thrombosis [DVT], Insufficiency)  
7. Each presenting author must comply with the SCAI Disclosure Policy and must provide the following: indication of the relationship, the associated commercial entity, and the level. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information, as applicable, or that they have nothing to disclose.
8. There is no limit on the number of authors for abstract submissions.  
9. All revisions must be made by the abstract submission deadline.  
10. The submitter acts on behalf of all co-authors and in submitting an abstract/late-breaking clinical science, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following:
    • All proprietary rights other than copyright, such as patent rights  
    • The right to use all or part of the application in future works of their own. SCAI and its new official journal, JSCAI, as holder of the copyright on the accepted application, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.  
11. Abstract acceptance notifications will be emailed to the addresses provided for the presenting authors, along with presentation guidelines.  
12. Requests to withdraw an abstract must be submitted in writing to abstracts@scai.org by February 14, 2022.   
13. SCAI promotes abstracts, late-breaking clinical science, research, and presentations to online, print, and broadcast media on behalf of Scientific Sessions.  
14. Embargoed content: All authors, presenters, company sponsors, attendees, journalists, and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies, which state that scientific study results presented during Scientific Sessions must not be released publicly prior to the embargo date and time. If the media contacts authors directly, authors, presenters, and/or company sponsors must first seek SCAI approval for information to be shared with the understanding that it is under embargo. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters, and/or company sponsors. SCAI leadership, press staff, and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., Securities and Exchange Commission requirements) must be met or in the case of a public health concern. The only exception to the above-mentioned embargo rules are closed investigator meetings for participants in the trial. The SCAI Program Committee may ask you to supply investigator meeting date/time/location information if your submission is accepted.  

Specific Embargo Dates and Times:  

*Oral Presentations: Abstracts selected for oral presentation are embargoed from the time of submission until conclusion of their presentations at Scientific Sessions.  

*Poster Presentations: Abstracts selected for poster presentation are embargoed from the time of submission until the start of Scientific Sessions.  

*Abstracts included in SCAI’s official Press Program are embargoed from the time of submission until conclusion of the press conference in which the research is presented or until conclusion of the presentation at the Scientific Sessions, whichever is first. Authors will be notified directly if their study has been selected for the Press Program, and the specific embargo details for their study will be provided. 

Abstract Availability

Embargoed text of abstracts, not in the Press Program, will be made available online two weeks prior to the start of Scientific Sessions. Note: The abstract embargo still applies; however, abstracts are made available to attendees to assist in creating their itineraries for the meeting. 

1. A case submission must include a case report and a PowerPoint presentation. The case report must be limited to 500 words (not including headers) and must contain the following sections: Title, Introduction, Clinical Case, and Discussion.
2. The SCAI Program Committee endorses the position of the American Association for the Advancement for Science (AAAS) in requiring assurances of the responsible use of animals in research. All submissions for consideration must follow these guidelines.  
3. Case submissions must fit into one of the following categories:   
   • Acute Coronary Syndromes and Myocardial Infarction (MI)  
   • Adult Congenital  
   • Angiogenesis, Myogenesis, Cell Therapy, and Gene Therapy  
   • Cardiogenic Shock and Hemodynamic Support  
   • Carotid Interventions  
   • Complex Percutaneous Coronary Intervention (PCI) and Restenosis (Excluding Left Main and Multivessel Intervention)  
   • Imaging: Computerized Tomography (CT), Magnetic Resonance Imaging (MR), and Noninvasive Imaging  
   • Intervention for Stable Ischemic Heart Disease  
   • Intravascular Imaging (Intravascular Ultrasound [IVUS]/Optical Coherence Topography [OCT]/Near Infrared [NIR]/Other) and Physiology (Fractional Flow Reserve [FFR]/Instantaneous Wave-Free Ratio [iFR]/Index of Microcirculatory Resistance [IMR]/Other)  
   • Left Main and Multivessel Intervention  
   • Miscellaneous  
   • Other Endovascular Interventions (Including Renal Denervation and Abdominal Aortic Aneurysm [AAA])  
   • Pediatric  
   • Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI)  
   • Pharmacotherapy  
   • Pulmonary Embolism  
   • Quality Improvement  
   • Structural Heart Disease (Excluding Valvular Interventions)  
   • Thrombectomy and Vulnerable Plaque  
   • Transcatheter Aortic Valve Replacement (TAVR)  
   • Valvular Interventions (Excluding TAVR)  
   • Vascular Access and Arterial Closure Devices  
   • Venous Disease (Including Deep Vein Thrombosis [DVT], Insufficiency)  
4. Each presenting author must comply with the SCAI Disclosure Policy and must provide the following: indication of the relationship, the associated commercial entity, and the level of support. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information, as applicable, or that they have nothing to disclose.  
5. There is no limit on the number of authors for case submissions.
6. All revisions must be made by the case submission deadline.  
7. The submitter acts on behalf of all co-authors and in submitting a case, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following:   
   • All proprietary rights other than copyright, such as patent rights
   • The right to use all or part of the application in future works of their own. SCAI and its new official journal, JSCAI, as holder of the copyright on the accepted application, reserves all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.
8. Case acceptance notifications will be emailed to the addresses provided for the presenting authors, along with presentation guidelines.  
9. Requests to withdraw a case must be submitted in writing to cases@scai.org by February 14, 2022.  

Coming Soon